Generic drugs
Lilly unlikely to gain from Plavix patent loss, analyst says
May 17, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more
of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection
Thursday.
MoreWellPoint won’t put brand-name Lipitor on generics list
December 1, 2011
Bloomberg NewsIndianapolis-based WellPoint Inc., the largest U.S. health insurer by enrollment, will favor a copy of the blockbuster cholesterol
medication made by Watson Pharmaceuticals Inc., the insurer said.
MoreZyprexa era comes to an end for Lilly
October 27, 2011
IBJ StaffOn Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller,
ending 15 years of highly lucrative sales.
MoreFDA approves first generic versions of Zyprexa
October 24, 2011
IBJ Staff and Associated PressFederal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales
of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.
MoreLilly: Vendors key after Zyprexa patent loss
October 24, 2011
J.K. WallLilly's patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more
on its 1,300 Indiana vendors.
MoreEli Lilly's Elanco unit blossoming at just the right time
July 30, 2011
Greg AndrewsAn investment firm projects that the Elanco animal-health business will generate sales of nearly $2 billion by 2012 and surpass
$3 billion by 2018.
MoreLilly wins appeals court ruling in Strattera patent case
July 29, 2011
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s
patent on attention-deficit treatment Strattera was invalid.
MoreLilly asks judge to reject U.K. Zyprexa case
July 5, 2011
Bloomberg NewsEli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge
in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
MoreLilly plans 10 drugs in final-stage trials by year's end
June 30, 2011
Bloomberg NewsLilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s
disease, up from seven in 2005, the Indianapolis-based company said Thursday.
MoreDrug industry outlook negative through 2012, Moody’s says
June 8, 2011
Bloomberg NewsEarnings growth will continue to slow in 2011 for most of the industry’s biggest companies, analyst predicts.
MoreGrowth in drug spending to slow as generics rise
May 18, 2011
Bloomberg NewsThe annual growth rate in spending on drugs may be cut in half over the next five years as people opt for less expensive generic
medicines over brand-name treatments, a health-care research group said Wednesday, highlighting the challenge pharmaceutical
firms like Eli Lilly and Co. are facing.
MoreTwo wins to bring Lilly modest sales
May 9, 2011
J.K. WallFinally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a
new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties
for the Indianapolis-based drugmaker.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreLechleiter: After the deluge, we'll be fine
March 16, 2011
J.K. WallEli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver
his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly
will be just fine after it has sustained the damage of the next three years.
MoreRecent successes don't change Lilly's outlook
February 9, 2011
J.K. WallEli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past
18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have
paltry sales prospects.
MoreLilly scores series of small victories
November 17, 2010
J.K. WallThe Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended
off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
MoreCourt upholds Lilly patent on cancer drug Alimta
November 16, 2010
IBJ Staff and Associated PressA U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound
until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of
patent expirations in coming years.
MoreAppeals court rejects Lilly over Gemzar patent
November 1, 2010
IBJ Staff and Bloomberg NewsWithout an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
MoreConsultants: Pharma industry facing huge changes
October 6, 2010
J.K. Wall
To date, most analysts say health reform turned out pretty well for
the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver
a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen
over the past three decades.
Lilly sues drug distributor over generic Zyprexa sales
September 29, 2010
Bloomberg NewsCelesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing
in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
MoreAppeals court ruling upholds Lilly's Evista patents
September 1, 2010
Bloomberg NewsEli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic
version of the Evista osteoporosis treatment before March 2014.
MoreLilly wins ban of generic Strattera pending appeal
August 31, 2010
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until
the court rules on a judge's decision invalidating a patent on the medicine.
MoreLilly wins further delay in sales of Strattera copies
August 26, 2010
Bloomberg NewsStrattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
MoreLilly wins temporary ban on sales of Strattera copies
August 19, 2010
Bloomberg NewsThe invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
MoreEli Lilly loses patent lawsuit for Strattera
August 13, 2010
IBJ Staff and Associated PressEli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
IBJ Featured Advertisers
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
graham. they are even better w/ roasted marshmallows and melted chocolate
Apparently ticket sales are slow too...mas emails have been sent by the speedway in a last ditch attempt to get place fans to come.
Garden Valley Veggie flavor Wheat Thins Toasted Chips. Don't judge until you try them, haters!
Doc, a few important errors in your statements:
(1) The developer is spending the CITY'S money (the city is paying for the cost of the garage), so the city can damn well insist on a quality design.
(2) The LAW requires the proposed building to comply with design standards, and insisting that people follow the law is not giving anyone the "run-around."
(3) A two-week delay to make some minimal aesthetic improvements is hardly a great imposition being imposed on the developer.
(4) If the developer would rather build a crappy building elsewhere with their own money, then they are welcome to pick up and do so.
(4) Indianapolis is a major city, not some podunk town that needs to spread its legs for any developer that throws the place a sideways glance. Indianapolis should insist on the best, not settle for junk. Accepting anything is not going to make Indianapolis grow any faster (not sure where you got that silly notion from), nor is Indianapolis a slow-growth city compared to similarly sized city's in the Midwest.
Alone. Or with cheese.